References
- Betts G, Jones E, Junaid S, El-Shanawany T, Scurr M, Mizen P, et al. Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut 2012; In press PMID: 22207629
- Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909 - 15; http://dx.doi.org/10.1038/nm1100; PMID: 15340416
- Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6:345 - 52; http://dx.doi.org/10.1038/ni1178; PMID: 15785760
- McCarty W. Principles of prognosis in cancer. J Am Med Assoc 1931; 96:30 - 3; http://dx.doi.org/10.1001/jama.1931.02720270032009
- Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960 - 4; http://dx.doi.org/10.1126/science.1129139; PMID: 17008531
- Clarke SL, Betts GJ, Plant A, Wright KL, El-Shanawany TM, Harrop R, et al. CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS One 2006; 1:e129; http://dx.doi.org/10.1371/journal.pone.0000129; PMID: 17205133
- Betts GJ, Clarke SL, Richards HE, Godkin AJ, Gallimore AM. Regulating the immune response to tumours. Adv Drug Deliv Rev 2006; 58:948 - 61; http://dx.doi.org/10.1016/j.addr.2006.05.006; PMID: 17070961
- Ladoire S, Martin F, Ghiringhelli F. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother 2011; 60:909 - 18; http://dx.doi.org/10.1007/s00262-011-1046-y; PMID: 21644034